Research Summary

My research concerns access, delivery, and organization of substance abuse treatment services. My experience in this area includes studies evaluating efforts to improve access to publicly funded drug abuse treatment, assessing federal policy to end addiction as an SSI disability category, evaluating needle exchange as an HIV prevention strategy, and investigating interventions for drug-involved offenders. In recent years, my work has focused on tobacco dependence in addictions treatment, because of the high rate of smoking in this population, because of the known health consequences, and because of the increasing evidence that quitting smoking in addictions treatment also improves drug abuse outcomes.

I recently accepted leadership of the Tobacco Control Program of the UCSF NCI-funded HDFCCC, and I program the Cancer Center’s tobacco control seminar that postdoctoral fellows attend as part of their broader training. In the past 5 years, I have led the NIDA-funded P50 Center of Excellence, in the Department of Psychiatry, dedicated to continuing and extended care models of addiction treatment. At the national level, I chair the NIH Dissemination and Implementation Research in Health (DIRH) review committee. I have a longstanding value on training the next generation of researchers. This is most apparent in our NIDA T32 postdoctoral fellowship training program in drug abuse treatment and services research, and in our more recent R25 designed to train underrepresented minority scientists in addiction treatment. In my career, I have had primary mentoring responsibilities for 16 pre and postdoctoral scholars, and for both clinical and research training.

Research Funding

  • September 30, 2013 - August 31, 2017 - Marketing, FDA communication, tobacco perceptions and use in addiction treatment , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01DA036066
  • September 29, 1994 - May 31, 2016 - Treatment for Complex Patients: Continuing and Extended Care , Principal Investigator . Sponsor: NIH, Sponsor Award ID: P50DA009253
  • April 20, 2006 - March 31, 2012 - Organizational Change and Nicotine Dependence Treatment , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01DA020705
  • August 1, 2009 - July 31, 2011 - Impact of Core Implementation Components on Adoption , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01DA025600


Washington State University, Pullman, WA, BS, 1977, Psychology
Fort Hays State University, Hays, KS, MS, 1982, Clinical Psychology
Washington State University, Pullman, WA, PhD, 1987, Clinical Psychology
University of California, San Francisco, CA, Postdoc Fellow, 1987-1988, Behavioral Medicine
University of California, San Francisco, Research Fellow, 1988-1990, AIDS Prevention Studies
University of California, Berkeley, CA, MPH, 1990, Epidemiology

Selected Publications

  1. Pagano A, McCuistian C, Le T, Campbell BK, Delucchi K, Woodward-Lopez G, Guydish J. Smoking Behavior and Wellness among Individuals in Substance Use Disorder Treatment. J Psychoactive Drugs. 2022 Jul 09; 1-12.  View on PubMed
  2. Fokuo JK, McCuistian CL, Masson CL, Gruber VA, Straus E, Wong J, Guydish JR. Pre-implementation Assessment of Tobacco Cessation Interventions in Substance Use Disorder Residential Programs in California. Subst Use Misuse. 2022; 57(9):1345-1355.  View on PubMed
  3. Martínez C, Feliu A, Torres N, Nieva G, Pinet C, Raich A, Mondon S, Barrio P, Andreu M, Hernández-Ribas R, Vicens J, Costa S, Suelves JM, Vilaplana J, Enríquez M, Alaustre L, Vilalta E, Subirà S, Bruguera E, Castellano Y, Saura J, Guydish J, Fernández E, Ballbè M. Acceptability and participation predictors for a pragmatic randomized controlled trial to test a smoking cessation intervention after discharge from mental health wards. Drug Alcohol Depend. 2022 05 01; 234:109390.  View on PubMed
  4. Fitzpatrick CM, Anderson BT, Agin-Liebes G, Guydish J. Comment and Response: (Lugo-Radillo & Cortez-Lopez, 2020) Long-Term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-Containing Mushrooms. J Psychoactive Drugs. 2022 Jan 27; 1-4.  View on PubMed
  5. McCuistian C, Kapiteni K, Le T, Safier J, Delucchi K, Guydish J. Reducing tobacco use in substance use treatment: An intervention to promote tobacco-free grounds. J Subst Abuse Treat. 2022 04; 135:108640.  View on PubMed
  6. McCuistian C, Le T, Delucchi K, Pagano A, Hosakote S, Guydish J. Racial/Ethnic Differences in Tobacco Use and Cessation Services among Individuals in Substance Use Treatment. J Psychoactive Drugs. 2021 Nov-Dec; 53(5):483-490.  View on PubMed
  7. Nguyen N, Kapiteni K, Straus ER, Guydish J. Factors associated with dual and polytobacco use among people in residential substance use disorder treatment. Am J Addict. 2021 09; 30(5):496-504.  View on PubMed
  8. Accurso EC, Mu KJ, Landsverk J, Guydish J. Adaptation to family-based treatment for Medicaid-insured youth with anorexia nervosa in publicly-funded settings: Protocol for a mixed methods implementation scale-out pilot study. J Eat Disord. 2021 Aug 13; 9(1):99.  View on PubMed
  9. Masson CL, McCuistian C, Straus E, Elahi S, Chen M, Gruber VA, Le T, Guydish J. COVID-19 vaccine trust among clients in a sample of California residential substance use treatment programs. Drug Alcohol Depend. 2021 08 01; 225:108812.  View on PubMed
  10. Guydish J, Le T, Hosakote S, Straus E, Wong J, Martínez C, Delucchi K. Tobacco use among substance use disorder (SUD) treatment staff is associated with tobacco-related services received by clients. J Subst Abuse Treat. 2022 01; 132:108496.  View on PubMed
  11. Masson CL, Le T, Hosakote S, Fokuo JK, Gubner NR, Shingle M, Guydish J. Correlates of e-cigarette use for smoking cessation among clients in residential substance use disorder treatment. Addict Behav. 2021 08; 119:106947.  View on PubMed
  12. Pagano A, Hosakote S, Kapiteni K, Straus ER, Wong J, Guydish JR. Impacts of COVID-19 on residential treatment programs for substance use disorder. J Subst Abuse Treat. 2021 04; 123:108255.  View on PubMed
  13. Guydish JR, Straus ER, Le T, Gubner N, Delucchi KL. Menthol cigarette use in substance use disorder treatment before and after implementation of a county-wide flavoured tobacco ban. Tob Control. 2021 11; 30(6):616-622.  View on PubMed
  14. Satre DD, Palzes VA, Young-Wolff KC, Parthasarathy S, Weisner C, Guydish J, Campbell CI. Healthcare utilization of individuals with substance use disorders following Affordable Care Act implementation in a California healthcare system. J Subst Abuse Treat. 2020 11; 118:108097.  View on PubMed
  15. Guydish J, Kapiteni K, Le T, Campbell B, Pinsker E, Delucchi K. Tobacco use and tobacco services in California substance use treatment programs. Drug Alcohol Depend. 2020 09 01; 214:108173.  View on PubMed
  16. Campbell BK, Le T, Kapiteni K, Gubner NR, Guydish J. Correlates of lifetime blunt/spliff use among cigarette smokers in substance use disorders treatment. J Subst Abuse Treat. 2020 09; 116:108064.  View on PubMed
  17. Martínez C, Feliu A, Castellano Y, Fu M, Fernández P, Cabrera-Jaime S, Puig-Llobet M, Galimany J, Guydish J, Fernández E, ETHIF Research Group. Factors associated with receipt of the 5As model of brief intervention for smoking cessation among hospitalized patients. Addiction. 2020 11; 115(11):2098-2112.  View on PubMed
  18. Yip D, Gubner N, Le T, Williams D, Delucchi K, Guydish J. Association of Medicaid Expansion and Health Insurance with Receipt of Smoking Cessation Services and Smoking Behaviors in Substance Use Disorder Treatment. J Behav Health Serv Res. 2020 04; 47(2):264-274.  View on PubMed
  19. Guydish J, Wahleithner J, Williams D, Yip D. Tobacco-free grounds implementation in California residential substance use disorder (SUD) treatment programs. J Addict Dis. 2020 Jan-Mar; 38(1):55-63.  View on PubMed
  20. Martínez C, Castellano Y, Fu M, Riccobene A, Feliu A, Tigova O, Ballbè M, Anton L, Fernández P, Cabrera-Jaime S, Puig-Llobet M, Moreno C, Falcó-Pegueroles A, Galimany J, Estrada JM, Guydish J, Fernández E, ETHIF Research Group. Patient perceptions of tobacco control after smoke-free hospital grounds legislation: Multi-center cross-sectional study. Int J Nurs Stud. 2020 Feb; 102:103485.  View on PubMed

Go to UCSF Profiles, powered by CTSI